Cargando…

Results of a Time and Motion Survey Regarding Subcutaneous versus Intravenous Administration of Daratumumab in Patients with Relapsed or Refractory Multiple Myeloma

PURPOSE: Daratumumab (DARA) is a humanized anti-CD38 monoclonal antibody and approved as monotherapy or in combination with standard of care regimens for the treatment of multiple myeloma (MM). DARA intravenous (IV) administration is time-consuming; availability of DARA subcutaneous (SC) is expected...

Descripción completa

Detalles Bibliográficos
Autores principales:	Slavcev, Mary, Spinelli, Allison, Absalon, Elisabeth, Masterson, Tara, Heuck, Christoph, Lam, Annette, De Cock, Erwin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2021
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8197571/ https://www.ncbi.nlm.nih.gov/pubmed/34135605 http://dx.doi.org/10.2147/CEOR.S302682

Ejemplares similares

Final analysis of the phase III non-inferiority COLUMBA study of subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma
por: Usmani, Saad Z., et al.
Publicado: (2022)

Subcutaneous daratumumab and hyaluronidase-fihj in newly diagnosed or relapsed/refractory multiple myeloma
por: Sanchez, Larysa, et al.
Publicado: (2021)

Subcutaneous daratumumab in patients with relapsed or refractory multiple myeloma: part 2 of the open-label, multicenter, dose-escalation phase Ib study (PAVO)
por: San-Miguel, Jesus, et al.
Publicado: (2020)

Selinexor, daratumumab, and dexamethasone in patients with relapsed or refractory multiple myeloma
por: Gasparetto, Cristina, et al.
Publicado: (2020)

B06: SUBCUTANEOUS TALQUETAMAB IN COMBINATION WITH DARATUMUMAB IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): PHASE 1B RESULTS
por: Mateos, M, et al.
Publicado: (2022)

Daratumumab, lenalidomide, and dexamethasone in relapsed/refractory myeloma: a cytogenetic subgroup analysis of POLLUX
por: Kaufman, Jonathan L., et al.
Publicado: (2020)

Pomalidomide, dexamethasone, and daratumumab in relapsed refractory multiple myeloma after lenalidomide treatment
por: Siegel, David S., et al.
Publicado: (2020)

Role of Daratumumab in Combination With Standard Therapies in Patients With Relapsed and Refractory Multiple Myeloma
por: Bapatla, Anusha, et al.
Publicado: (2021)

Daratumumab, carfilzomib, and dexamethasone in relapsed or refractory myeloma: final analysis of PLEIADES and EQUULEUS
por: Moreau, Philippe, et al.
Publicado: (2023)

Pharmacokinetics of Daratumumab Following Intravenous Infusion in Relapsed or Refractory Multiple Myeloma After Prior Proteasome Inhibitor and Immunomodulatory Drug Treatment
por: Clemens, Pamela L., et al.
Publicado: (2016)

Daratumumab for the Management of Newly Diagnosed and Relapsed/Refractory Multiple Myeloma: Current and Emerging Treatments
por: Offidani, Massimo, et al.
Publicado: (2021)

NK Cell Phenotype Is Associated With Response and Resistance to Daratumumab in Relapsed/Refractory Multiple Myeloma
por: Verkleij, Christie P.M., et al.
Publicado: (2023)

Efficacy and Safety of Durvalumab Combined with Daratumumab in Daratumumab-Refractory Multiple Myeloma Patients
por: Frerichs, Kristine A., et al.
Publicado: (2021)

Safety and blood levels of daratumumab after switching from intravenous to subcutaneous administration in patients with multiple myeloma
por: Yamaoka, Kenta, et al.
Publicado: (2023)

Influence of Disease and Patient Characteristics on Daratumumab Exposure and Clinical Outcomes in Relapsed or Refractory Multiple Myeloma
por: Yan, Xiaoyu, et al.
Publicado: (2017)

Clinical Implications of Complex Pharmacokinetics for Daratumumab Dose Regimen in Patients With Relapsed/Refractory Multiple Myeloma
por: Xu, XS, et al.
Publicado: (2017)

Daratumumab as Single Agent in Relapsed/Refractory Myeloma Patients: A Retrospective Real-Life Survey
por: Markovic, Uros, et al.
Publicado: (2021)

Laboratory features of tumour lysis syndrome following daratumumab monotherapy in relapsed/refractory multiple myeloma
por: Shackleton, Louisa, et al.
Publicado: (2020)

Efficacy and safety of daratumumab combined with all-trans retinoic acid in relapsed/refractory multiple myeloma
por: Frerichs, Kristine A., et al.
Publicado: (2021)

Daratumumab Improves Bone Turnover in Relapsed/Refractory Multiple Myeloma; Phase 2 Study “REBUILD”
por: Terpos, Evangelos, et al.
Publicado: (2022)

Daratumumab triplet therapies in patients with relapsed or refractory multiple myeloma: A “real world” experience
por: Fucci, Ludovica, et al.
Publicado: (2022)

Role of daratumumab in relapsed or refractory multiple myeloma patient: A meta-analysis and literature to review
por: Tauseef, Abubakar, et al.
Publicado: (2022)

Predictive role of absolute lymphocyte count in daratumumab-treated patients with relapsed/refractory multiple myeloma
por: Cho, Hee Jeong, et al.
Publicado: (2023)

Phase II trial of daratumumab with DCEP in relapsed/refractory multiple myeloma patients with extramedullary disease
por: Byun, Ja Min, et al.
Publicado: (2022)

Daratumumab with lenalidomide and dexamethasone in relapsed or refractory multiple myeloma patients – real world evidence analysis
por: Stork, Martin, et al.
Publicado: (2023)

Predictive role of absolute lymphocyte count in daratumumab-treated patients with relapsed/refractory multiple myeloma
por: Cho, Hee Jeong, et al.
Publicado: (2023)

Clinical Administration Characteristics of Subcutaneous and Intravenous Administration of Daratumumab in Patients With Multiple Myeloma at Mayo Clinic Infusion Centers
por: Soefje, Scott A., et al.
Publicado: (2023)

Daratumumab plus lenalidomide and dexamethasone versus lenalidomide and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of POLLUX
por: Dimopoulos, Meletios A., et al.
Publicado: (2018)

Results of an early access treatment protocol of daratumumab in United States patients with relapsed or refractory multiple myeloma
por: Chari, Ajai, et al.
Publicado: (2018)

Results of an Early Access Treatment Protocol of Daratumumab Monotherapy in Spanish Patients With Relapsed or Refractory Multiple Myeloma
por: Alegre, Adrián, et al.
Publicado: (2020)

Daratumumab, bortezomib, and dexamethasone in relapsed or refractory multiple myeloma: subgroup analysis of CASTOR based on cytogenetic risk
por: Weisel, Katja, et al.
Publicado: (2020)

Daratumumab Monotherapy for Relapsed or Refractory Multiple Myeloma: Results of an Early Access Treatment Protocol in Europe and Russia
por: Cook, Gordon, et al.
Publicado: (2021)

Efficacy and Safety of Daratumumab, Pomalidomide, and Dexamethasone (DPd) Compared to Daratumumab, Bortezomib, and Dexamethasone (DVd) in Daratumumab–Naïve Relapsed Multiple Myeloma
por: Afrough, Aimaz, et al.
Publicado: (2023)

B04: COMBINATION OF SUBCUTANEOUS TECLISTAMAB WITH DARATUMUMAB IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): RESULTS FROM A PHASE 1B MULTICOHORT STUDY
por: Rodriguez-Otero, P, et al.
Publicado: (2022)

Exposure‐Response and Population Pharmacokinetic Analyses of a Novel Subcutaneous Formulation of Daratumumab Administered to Multiple Myeloma Patients
por: Luo, Man (Melody), et al.
Publicado: (2020)

Indirect Treatment Comparison of Daratumumab, Pomalidomide, and Dexamethasone Versus Standard of Care in Patients with Difficult-to-Treat Relapsed/Refractory Multiple Myeloma
por: He, Jianming, et al.
Publicado: (2022)

Daratumumab plus bortezomib and dexamethasone versus bortezomib and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of CASTOR
por: Spencer, Andrew, et al.
Publicado: (2018)

Efficacy of retreatment with immunomodulatory drugs and proteasome inhibitors following daratumumab monotherapy in relapsed and refractory multiple myeloma patients
por: Oostvogels, Rimke, et al.
Publicado: (2018)

Multiagent therapy with pomalidomide, bortezomib, doxorubicin, dexamethasone, and daratumumab (“Pom‐PAD‐Dara”) in relapsed/refractory multiple myeloma
por: Zhou, Xiang, et al.
Publicado: (2020)

Results of the daratumumab monotherapy early access treatment protocol in patients from Brazil with relapsed or refractory multiple myeloma()
por: Crusoé, Edvan de Queiroz, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_eqroj7973vtpe93vc69n023fsp